Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

LANNETT COMPANY, INC. (LCI)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2018 713 M
EBIT 2018 241 M
Net income 2018 88,4 M
Debt 2018 771 M
Yield 2018 -
Sales 2019 705 M
EBIT 2019 224 M
Net income 2019 87,4 M
Debt 2019 718 M
Yield 2019 -
P/E ratio 2018 13,37
P/E ratio 2019 14,54
EV / Sales2018 2,58x
EV / Sales2019 2,54x
Capitalization 1 068 M
More Financials
Company
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products.Its pharmaceutical products are distributed to drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers,... 
Sector
Pharmaceuticals
Calendar
12/14Presentation
More about the company
Surperformance© ratings of Lannett Company, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on LANNETT COMPANY, INC.
12/07 LANNETT : Announces Agreement For Authorized Generic Version Of Toprol-XL®
12/07 LANNETT : Announces FDA Acceptance Of 505b2 New Drug Application For Cocaine Hyd..
12/04 LANNETT : Announces FDA Acceptance Of 505(b)(2) New Drug Application For Cocaine..
12/01 LANNETT : Announces Agreement For Authorized Generic Version Of Toprol-XL
12/01 LANNETT : Announces FDA Acceptance Of 505(b)(2) New Drug Application For Cocaine..
11/29 LANNETT : Announces Agreement For Authorized Generic Version Of Toprol-XL®
11/28 SCOTT+SCOTT, ATTORNEYS AT LAW, LLP : is Investigating Derivative Claims on Behal..
11/14 LANNETT : To Present At The Jefferies 2017 London Healthcare Conference On Novem..
11/09 LANNETT : And Celgene Enter Into Settlement And License Agreement Related To Tha..
11/09 SCOTT+SCOTT, ATTORNEYS AT LAW, LLP : is Investigating Derivative Claims on Behal..
More news
Sector news : Pharmaceuticals - NEC
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 ALEXION PHARMACEUTICALS : Elliott Management seeks changes at Alexion - NYT
12/08 Wall Street closes higher after payrolls report
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,1 $
Spread / Average Target -8,0%
EPS Revisions
Managers
NameTitle
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
John Kozlowski Chief Operating Officer, VP-Financial Operations
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.1 068
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559